Trial Profile
A study of Palbociclib in highly pretreated metastatic ER-positive HER-2 negative breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 11 Jan 2018
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Megestrol; Tamoxifen
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Expanded access; Therapeutic Use
- 11 Jan 2018 New trial record
- 09 Dec 2017 An updated data will be presented at conference.
- 09 Dec 2017 Results (n=68) of retrospective analysis assessing safety and efficacy presented at the 40th Annual San Antonio Breast Cancer Symposium